Skip to main content
. 2015 Sep 3;10(9):e0136558. doi: 10.1371/journal.pone.0136558

Table 1. Patient data.

At diagnosis At end of study
Patient Gender Age Treatment Up/c eGFR Albumin Histologic type Up/c eGFR Primary outcome (1–6)
1 M 10 CSA 1.98 184.9 2.9 NOS 2.35 264.4 4
2 F 14 CSA 2.63 164.7 3.4 NOS 0.41 150.8 3
3 F 14 CSA 4.34 171.1 3.2 NOS 0.45 144 3
4 F 37 CSA 3.28 76.5 3.6 NOS 0.75 71.7 2
5 M 12 CSA 2.85 112.2 3.6 Perihilar 0.36 108.2 4
6 M 35 CSA 1.29 56.4 3.6 NOS 0.8 47.9 6
7 M 26 CSA 2.76 83.3 3.4 Perihilar 1.46 56.7 3
8 M 27 MMF 3.94 84 3.3 Tip 1.73 77.9 4
9 F 35 MMF 2.95 95.3 3.6 Collapsing 2.77 32.8 6
10 M 37 MMF 2.58 53.8 4.0 NOS 3.56 26 6
11 M 36 MMF 2.26 127.8 3.4 Tip 0.56 149.2 3
12 F 34 MMF 2.17 64.0 3.4 Perihilar 2.75 58.4 3
13 M 30 MMF 1.04 111.2 4.6 Tip 0.21 105.9 3
14 M 15 MMF 3.15 152.3 2.8 NOS 0.07 154.9 1
15 F 14 MMF 4.76 53.7 3.4 Perihilar 1.63 44.2 3
16 M 13 MMF 15.22 87.9 1.2 Collapsing - - 6
17 F 13 MMF 15.31 86.6 2.2 Tip 0.06 132.8 2
18 F 26 MMF 4.07 189.1 3.8 NOS 1.64 224.2 3
19 F 12 MMF 1.04 206.3 3.7 NOS 0.06 178.6 1

Abbreviations: cyclosporine, CSA; mycophenolate mofetil, MMF; Not otherwise specified, NOS.